We are live on ! Find out more
TVTX icon

Travere Therapeutics

321 hedge funds and large institutions have $5.98B invested in Travere Therapeutics in 2026 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 123 increasing their positions, 85 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more first-time investments, than exits

New positions opened: 89 | Existing positions closed: 29

175% more funds holding in top 10

Funds holding in top 10: 4 → 11 (+7)

105% more capital inflows, than outflows

Capital inflows: $1.39B | Capital outflows: $676M

55% more call options, than puts

Call options by funds: $77.8M | Put options by funds: $50.1M

45% more repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 85

22% more funds holding

Funds holding: 263 → 321 (+58)

4.27% more ownership

Funds ownership: 109.9% → 114.17% (+4.3%)

Holders
321
Holders Change
+58
Holders Change %
+22.05%
% of All Funds
3.82%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.13%
New
89
Increased
123
Reduced
85
Closed
29
Calls
$77.8​M
Puts
$50.1​M
Net Calls
+$27.7​M
Net Calls Change
+$500​K

TVTX Hedge Fund Activity: Q2 2026 in Review

321 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2026, worth a combined $5.98B — up 99% from $3.01B a quarter earlier.

Buyers outnumbered sellers: 89 funds opened new TVTX positions and 29 closed out — a net gain of 60 holders — while 123 added to existing stakes and 85 trimmed.

The largest buyer was Bank of America, adding an estimated $143M. The largest seller was Fidelity Investments, cutting an estimated $172M.

  • 321 institutional investors held Travere Therapeutics (TVTX) as of Q2 2026, up from 263 in Q1 2026.
  • Funds reported $5.98B of Travere Therapeutics stock for Q2 2026, up 99% quarter-over-quarter.
  • 89 funds opened new Travere Therapeutics positions in Q2 2026 and 29 closed out, a net change of +60 holders.
  • The largest Travere Therapeutics buyer in Q2 2026 was Bank of America, an estimated $143M added.
  • The largest Travere Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $172M sold.

Based on aggregated 13F filings for Q2 2026.